 Ribosomal Protein S6 Kinases, 70-kDa
"Ribosomal Protein S6 Kinases, 70-kDa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of ribosomal protein S6 kinases that are considered the major physiological kinases for RIBOSOMAL PROTEIN S6. Unlike RIBOSOMAL PROTEIN S6 KINASES, 90KDa the proteins in this family are sensitive to the inhibitory effects of RAPAMYCIN and contain a single kinase domain. They are referred to as 70kDa proteins, however ALTERNATIVE SPLICING of mRNAs for proteins in this class also results in 85kDa variants being formed.
| Descriptor ID |
D038762
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.862.249 D12.644.360.600.249 D12.776.476.600.249
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ribosomal Protein S6 Kinases, 70-kDa".
Below are MeSH descriptors whose meaning is more specific than "Ribosomal Protein S6 Kinases, 70-kDa".
This graph shows the total number of publications written about "Ribosomal Protein S6 Kinases, 70-kDa" by people in this website by year, and whether "Ribosomal Protein S6 Kinases, 70-kDa" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 | | 2003 | 1 | 1 | 2 | | 2004 | 3 | 0 | 3 | | 2005 | 1 | 1 | 2 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 4 | 4 | | 2008 | 0 | 1 | 1 | | 2009 | 2 | 0 | 2 | | 2011 | 2 | 1 | 3 | | 2012 | 1 | 3 | 4 | | 2014 | 1 | 1 | 2 | | 2018 | 2 | 1 | 3 | | 2019 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Ribosomal Protein S6 Kinases, 70-kDa" by people in Profiles.
-
Wang J, Prinz RA, Liu X, Xu X. In Vitro and In Vivo Antiviral Activity of Gingerenone A on Influenza A Virus Is Mediated by Targeting Janus Kinase 2. Viruses. 2020 10 08; 12(10).
-
Sural-Fehr T, Singh H, Cantuti-Catelvetri L, Zhu H, Marshall MS, Rebiai R, Jastrzebski MJ, Givogri MI, Rasenick MM, Bongarzone ER. Inhibition of the IGF-1-PI3K-Akt-mTORC2 pathway in lipid rafts increases neuronal vulnerability in a genetic lysosomal glycosphingolipidosis. Dis Model Mech. 2019 05 23; 12(5).
-
Chen J, Sun J, Prinz RA, Li Y, Xu X. Gingerenone A Sensitizes the Insulin Receptor and Increases Glucose Uptake by Inhibiting the Activity of p70 S6 Kinase. Mol Nutr Food Res. 2018 12; 62(23):e1800709.
-
Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
-
Sun J, Mu Y, Jiang Y, Song R, Yi J, Zhou J, Sun J, Jiao X, Prinz RA, Li Y, Xu X. Inhibition of p70 S6 kinase activity by A77 1726 induces autophagy and enhances the degradation of superoxide dismutase 1 (SOD1) protein aggregates. Cell Death Dis. 2018 03 14; 9(3):407.
-
Steinhardt JJ, Peroutka RJ, Mazan-Mamczarz K, Chen Q, Houng S, Robles C, Barth RN, DuBose J, Bruns B, Tesoriero R, Stein D, Fang R, Hanna N, Pasley J, Rodriguez C, Kligman MD, Bradley M, Rabin J, Shackelford S, Dai B, Landon AL, Scalea T, Livak F, Gartenhaus RB. Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase. Blood. 2014 Dec 11; 124(25):3758-67.
-
Hollebecque A, Houédé N, Cohen EE, Massard C, Italiano A, Westwood P, Bumgardner W, Miller J, Brail LH, Benhadji KA, Soria JC. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours. Eur J Cancer. 2014 Mar; 50(5):876-84.
-
Geslain R, Uddin S, Liu H, Jiang H, van Besien K, Pan T, Wickrema A. Distinct functions of erythropoietin and stem cell factor are linked to activation of mTOR kinase signaling pathway in human erythroid progenitors. Cytokine. 2013 Jan; 61(1):329-35.
-
Cohen EE, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, Nallari A, Maitland ML, Fox-Kay K, Moshier K, House L, Ramirez J, Undevia SD, Fleming GF, Gajewski TF, Ratain MJ. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012 Sep 01; 18(17):4785-93.
-
Chuu CP, Lin HP, Ciaccio MF, Kokontis JM, Hause RJ, Hiipakka RA, Liao S, Jones RB. Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signaling networks. Cancer Prev Res (Phila). 2012 May; 5(5):788-97.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|